The FDA amended the vaccine’s emergency use authorization to allow a single booster dose six months after completion of the primary series for individuals ages 65 and older, 18-64 at high risk of severe COVID-19, or 18-64 “whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of COVID-19, including […]